Impairment of vascular and platelet levels of nitric oxide and cyclic guanosine-′,5′-monophosphate in cyclosporin A-induced hypertensive rats

Fundamental and Clinical Pharmacology

Volumn 17, Issue 1, 2003, Pages 43-50

  Santiago, Margarida ^a   Reis, Flávio ^a   Almeida, Luís ^a   Alcobia, Teresa ^a   Dionísio, Joaquim ^a   Teixeira, Frederico ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

cGMP; Cyclosporin; Hypertension; Nitric oxide; Platelets; Rat aorta

Indexed keywords

CYCLIC GMP; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; NITRITE;

ANIMAL CELL; ANIMAL MODEL; AORTA WALL; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; VASCULAR ENDOTHELIUM; VASCULAR RING;

ANIMALS; AORTA; BLOOD PLATELETS; CYCLIC GMP; CYCLOSPORINE; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; RATS; RATS, WISTAR; VASODILATION;

EID: 0037326672     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00116.x     Document Type: Article

References (49)

1. Kahan B.D. Cyclosporine. N. Engl. J. Med. (1989) 321 1725-1738.
2. Vanrenterghem Y., Roels L., Lerut T. et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaverickidney allograft recipients. Lancet (1985) i 999-1002.
3. McNally P.G., Feehally J. Pathophysiology of cyclosporin Anephrotoxicity: experimental and clinical observations. Nephrol. Dial. Transplant. (1992) 7 791-804.
4. Schachter M. Cyclosporine A and hypertension. J. Hypertens. (1988) 6 511-516.
5. Curtis J.J. Cyclosporine and posttransplant hypertension. J. Am. Soc. Nephrol. (1992) 2(Suppl. 1) S243-S245.
6. Cartier R., Dagenais F., Hollmann C., Cambron H., Buluran J. Chronic exposure to cyclosporine affects endothelial and smooth muscle reactivity in the rat aorta. Ann. Thorac. Surg. (1994) 58 789-794.
7. Zoja C., Furci L., Ghilardi F., Zilio P., Benigni A., Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab. Invest. (1986) 55 455-462.
8. Xue H., Buroski R.D., McCarron D.A., Bennett W.M. Induction of contraction in isolated rat aorta by cyclosporine. Transplantation (1987) 43 715-718.
9. Lamb F.S., Webb R.C. Cyclosporine augments reactivity of isolated blood vessels. Life Sci. (1987) 40 2571-2578.
10. Golub M.S., Lusting S., Berger M.E., Lee D.B.N. Altered vascular responses in cyclosporine-treated rats. Transplantation (1989) 48 116-118.
11. Rego A., Vargas R., Suarez K.R., Foegh M.L., Ramwell P.W. Mechanism of cyclosporine potentiation of vasoconstriction of the isolated rat mesenteric arterial bed: role of extracellular calcium. J. Pharmacol. Exp. Ther. (1990) 254 799-808.
12. Reis F., Tavares P., Rito L.C. et al. Platelet activation is increased in cyclosporin A-induced hypertensive rats. J. Cardiovasc. Pharmacol. (2000) 36 56-64.
13. Haug C., Duell T., Voisard R. et al. Cyclosporine A stimulates endothelin release. J. Cardiovasc. Pharmacol. (1995) 26 S239-S241.
14. Reis F., Tavares P., Fontes-Ribeiro C.A., Ferrer-Antunes C., Teixeira F. The peripheral serotonergic system and platelet aggregation in cyclosporin A-induced hypertensive rats. Thromb. Res. (1999) 96 365-372.
15. Lee D.B.N. Cyclosporine and the rennin-angiotensin axis. Kidney Int. (1997) 52 248-260.
16. Reis F., Tavares P., Teixeira F. The distribution of catecholamines between plasma and platelets in cyclosporin A-induced hypertensive rats. Pharmacol. Res. (2000) 41 129-135.
17. Scherrer U., Vissing S.F., Morgan B.J. et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N. Engl. J. Med. (1990) 323 693-699.
18. Sander M. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am. J. Hypertens. (1996) 9 121S-138S
19. Stephan D., Billing A., Krieger J.P. et al. Endothelium-dependent relaxation in the isolated rat kidney: impairment by cyclosporine A. J. Cardiovasc. Pharmacol. (1995) 26 859-868.
20. Rego A., Vargas R., Wroblewska B., Foegh M.L., Ramwell P.W. Attenuation of vascular relaxation and cyclic GMP responses by cyclosporin A. J. Pharmacol. Exp. Ther. (1990) 252 165-170.
21. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. (1993) 329 2002-2012.
22. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev. (1991) 43 109-142.
23. Luscher T.F., Noll G. The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis (1995) 118(Suppl.) S81-S90.
24. Radomski M.W., Palmer R.M.J., Moncada S. An L-arginine/nitricoxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad. Sci. USA (1990) 87 5193-5197.
25. Mehta J.L., Chen L.Y., Kone B.C., Mehta P., Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J. Lab. Clin. Med. (1995) 125 370-377.
26. White J.G. Platelets and atheriosclerosis. Eur. J. Clin. Invest. (1994) 24 25-29.
27. Erne P., Resink T., Buhler F. Platelets and hypertension. J. Cardiovasc. Pharmacol. (1985) 7(Suppl VI) S103-S108.
28. Cadwgan T.M., Benjamin N. Evidence for altered platelet nitric oxide synthesis in essential hypertension. J. Hypertens. (1993) 11 417-420.
29. Russell R.J. Use of arginine analogs as inhibitors of nitric oxide synthase in rat-aortic rings, in: Titheradge M.A. (Ed.), Nitric oxide protocols. Humana Press, Totowa, NJ, 1998. pp. 243-250.
30. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate nitrite, and [15N] nitrate in biological fluids. Anal. Biochem. Pharmacol. (1982) 126 131-138.
31. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. (1976) 72 248-254.
32. Auch-Schwelk W., Bossaller C., Gotze S., Thelen J., Fleck E. Endothelial and vascular smooth muscle function after chronic treatmentwith cyclosporin A. J. Cardiovasc. Pharmacol. (1993) 21 435-440.
33. Kim H.S., Kim D.H., Kang S.W. et al. L-Arginine restores suppressed acetylcholine-induced endothelium-dependent vascularrelaxation in cyclosporin A-treated rats. Transplant. Proc. (1996) 28 1372-1374.
34. Mathieu P., Carrier M., Dupuis J., Ryan J., Pelletier L.C. L-Arginine prevents cyclosporin A-induced pulmonary vascular dysfunction. Ann. Thorac. Surg. (1997) 64 414-420.
35. Oriji G.K., Keiser H.R. Role of nitric oxide in cyclosporin A-induced hypertension. Hypertension (1998) 32 849-855.
36. Oriji G.K., Keiser H.R. Nitric oxide in cyclosporin A-induced hypertension: role of protein kinase C. Am. J. Hypertens. (1999) 12 1091-1097.
37. Lee J., Kim S.W., Kook H., Kang D.G., Kim N.H., Choi K.C. Effects of L-arginine on cyclosporin-induced alterations of vascular NO/cGMP generation. Nephrol. Dial. Transplant. (1999) 14 2634-2638.
38. Akita K., Dusting G.J., Hickey H. Suppression of nitric oxideproduction by cyclosporin A and FK506 in rat vascular smooth muscle cells. Clin. Exp. Pharmacol. (1994) 21 231-233.
39. Marumo T., Nakaki T., Hishikawa K., Suzuki H., Kato R., Saruta T. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension (1995) 25(Part 2) 764-768.
40. Vaziri N.D., Ni Z., Zhang Y.P., Ruzics E.P., Maleki P., Ding Y. Depressed renal and vascular nitric oxide synthase expression in cyclosporine-induced hypertension. Kidney Int. (1998) 54 482-491.
41. O'Neil G.S., Chester A.H., Kushwaha S., Rose M., Tadjkarimi S., Yacoub M.H. Cyclosporin treatment does not impair the release of nitric oxide in human coronary arteries. Br. Heart J. (1991) 66 212-216.
42. Bobadilla N.A., Tapia E., Franco M. et al. Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int. (1994) 46 773-779.
43. Hansen J.M., Johansen N.J., Mollerup H.M., Anderson N.F., Strandgaard S. Effects of nitric oxide blockade and cyclosporin A on cardiovascular and renal function in normal man. J. Hypertens. (1999) 17 1707-1713.
44. Assis S.M., Monteiro J.L., Seguro A.C. L-arginine and allopurinol protect against cyclosporine nephrotoxicity. Transplantation (1997) 63 1070-1073.
45. Stroes E.S., Luscher T.F., Groot F.G., Koomans H.A., Rabelink T.J. Cyclosporin A increases nitric oxide activity in vivo. Hypertension (1997) 29 570-575.
46. Diederich D., Skopec J., Diederich A., Dai A. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension (1994) 23 957-961.
47. Roullet J.B., Xue H., McCarron D.A., Holcomb S., Bennett W.M. Vascular mechanisms of cyclosporin-induced hypertension in the rat. J. Clin.Invest. (1994) 93 2244-2250.
48. Rego A., Vargas R., Cathapermal S., Kuwahara M., Foegh M.L., Ramwell P.W. Systemic vascular effects of cyclosporin A treatment innormotensive rats. J. Pharmacol. Exp. Ther. (1991) 259 905-915.
49. Huang H.C., Rego A., Vargas R., Foegh M.L., Ramwell P.W. Nitroprusside-induced vascular relaxation is attenuated in organ-transplanted animals treated with cyclosporine. Transplant. Proc. (1987) 19 126-130.